SCHEMBL7613685

SCHEMBL7613685

O=C(O)CCCC(c1ccccn1)P(=O)(O)Cc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
SLC6A3 Q01959 2/20 0.39
HDAC3 O15379 1/20 0.39
MAPK1 P28482 1/20 0.39
ADRA1A P35348 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC10 Q969S8 1/20 0.39
HDAC11 Q96DB2 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HDAC9 Q9UKV0 1/20 0.39
HDAC5 Q9UQL6 1/20 0.39
ALDH1A1 P00352 3/20 0.38
GAA P10253 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5134278 0.81 ACP3 (0.49) SMN1; SMN2SLC6A3HDAC3MAPK1ADRA1A
SCHEMBL7614449 0.81 TBXAS1 (0.40) KDM4ESMN1; SMN2SLC6A3HDAC3MAPK1
SCHEMBL5053039 0.78 TBXAS1 (0.55)
SCHEMBL5051255 0.74 HDAC3 (0.38) SMN1; SMN2SLC6A3HDAC3MAPK1ADRA1A
SCHEMBL7614373 0.74 ACP3 (0.55) CYP1A2HTTCYP2C19
SCHEMBL7608849 0.74 CYP1A2 (0.47) SMN1; SMN2SLC6A3HDAC3MAPK1ADRA1A
SCHEMBL5054481 0.71 HDAC3 (0.46) KDM4EHDAC3HDAC4HDAC1HDAC7
SCHEMBL5053127 0.71 CETP (0.38) KDM4ESMN1; SMN2ALDH1A1CYP1A2HTT
SCHEMBL5058050 0.69 HDAC3 (0.41) SMN1; SMN2SLC6A3HDAC3MAPK1ADRA1A
SCHEMBL5060126 0.69 GGH (0.55) SMN1; SMN2SLC6A3HDAC3MAPK1ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020151503-A1 Methods of cancer treatment using naaladase inhibitors SLUSHER BARBARA S (US) 2002-10-17 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020151503-A1 Methods of cancer treatment using naaladase inhibitors NAALAD2, DNPEP, ACP3 KDM4E 1114/4885SMN1; SMN2 4380/4885SLC6A3 1361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.